Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|December 1, 2013
- Applied Clinical Trials-12-01-2013
- Volume 22
- Issue 12
Applied Clinical Trials Digital Edition - December 2013/January 2014
Clinical Technologies Survey Trial Design: Clinical Trial Design Automation CRO/Sponsor: Developing a Successful Peer-to-Peer Mentoring Program Also in this issue: Dealing with Europe's Antibiotic Research Gap Leveraging the Internet for Clinical Research How to Improve Virtual CRA Meetings
Advertisement
Articles in this issue
almost 13 years ago
On Trial—Europe's Response to Antibiotic Research Gapalmost 13 years ago
Clinical Trial Design Automationalmost 13 years ago
Clinical Supply Issues Challenge Sponsors and Patientsalmost 13 years ago
Reasons for Clinical Failures by Phasealmost 13 years ago
Act Coveralmost 13 years ago
Clearing the Way for the Internet of Thingsalmost 13 years ago
Developing a Successful Peer-to-Peer Mentoring Programalmost 13 years ago
Clinical Technologiesalmost 13 years ago
Jury's Still Out on How Best to Handle Trial Dataalmost 13 years ago
Exciting Changes for Applied Clinical Trials in 2014Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
4
Where AI Governance in Clinical Development Falls Short
5